Theriva Biologics, Inc. (TOVX) stock
TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.12−0.01 (-6.25%)
Close on Nov 20, 2026Market cap $5.51MP/E –Yield –
Theriva Biologics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Theriva Biologics's net income for the twelve months ending Dec 31, 2023 was -$18.35M. For fiscal 2023 it was -$18.35M. The highest annual figure on record is -$1.71M in fiscal 2010.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$18.35M | – |
| FY2022 | Dec 31, 2022 | -$19.69M | – |
| FY2021 | Dec 31, 2021 | -$14.27M | – |
| FY2020 | Dec 31, 2020 | -$10.04M | – |
| FY2019 | Dec 31, 2019 | -$15.30M | – |
| FY2018 | Dec 31, 2018 | -$13.37M | – |
| FY2017 | Dec 31, 2017 | -$15.17M | – |
| FY2016 | Dec 31, 2016 | -$27.26M | – |
| FY2015 | Dec 31, 2015 | -$43.74M | – |
| FY2014 | Dec 31, 2014 | -$19.78M | – |
| FY2013 | Dec 31, 2013 | -$12.32M | – |
| FY2012 | Dec 31, 2012 | -$17.07M | – |
| FY2011 | Dec 31, 2011 | -$8.15M | – |
| FY2010 | Dec 31, 2010 | -$1.71M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$5.49M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.49M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.48M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.27M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.26M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.27M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.54M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.11M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.87M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.96M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.14M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.12M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.53M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.19M | -213.5% |
| Q3 FY2018 | Sep 30, 2018 | -$3.68M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.20M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.32M | – |
| Q4 FY2017 | Dec 31, 2017 | $2.81M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.93M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.32M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.06M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.47M | – |
| Q3 FY2016 | Sep 30, 2016 | -$8.49M | – |
See a number that looks wrong?